EGFR and hepatocellular carcinoma: An in-silico molecular docking was conducted by Suganya and Anuradha, to evaluate the interaction of astaxanthin and sorafenib, a positive control drug with growth factor receptors such as VEGFR2 and EGFR, as well as apoptotic proteins like BCL-2, Caspase 3, and Caspase 9 to elucidate their anticancer mechanisms in hepatocellular carcinoma (HCC) cell line.